Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Yost

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Nuclear Medicine and Biology|October 1, 1996
Synthesis and preliminary evaluation of (S)-(2-[18F]fluoro-4,5-dihydroxyphenyl)-2-methyl L-alanine, (S)-[18F]-FMEDOPA, a potentially improved imaging agent for the presynaptic dopaminergic nervous systemY Yost, T Conway
Journal of Pharmaceutical Sciences|September 1, 1979
Resolution of (+/-)-propranololY Yost, J L Holtzman
Carcinogenesis|January 1, 1982
Effects of prolonged oral treatment with N-fluoren-4-ylacetohydroxamic acid on rat liver fine structureB Flaks, Y Yost, A Flaks
Cancer Research|February 1, 1975
The carcinogenicity of fluorenylhydroxamic acids and N-acetoxy-N-fluorenylacetamides for the rat as related to the reactivity of the esters toward nucleophilesY Yost, H R Gutmann, R E Rydell
Cancer Research|June 1, 1971
Activation of the carcinogen, N-hydroxy-2-fluorenylbenzene-sulfonamide, by desulfonylation to N-2-fluorenylhydroxylamine in vivoD Malejka-Giganti, H R Gutmann, R E Rydell, et al.
Molecular Pharmacology|November 1, 1981
Application of spin labeling to drug assays. II. Determination of the binding of [14C]-phenytoin and spin-labeled phenytoins to albumin and human serumD Chou, C F Polnaszek, Y Yost, et al.
Biochemical Pharmacology|May 25, 1993
Nitroxyl analogs as inhibitors of aldehyde dehydrogenase. C-nitroso compoundsH T Nagasawa, Y Yost, J A Elberling, et al.
Cancer Research|May 1, 1970
Structure-activity relationships of N-acylarylhydroxylamines in the ratH R Gutmann, D S Leaf, Y Yost, et al.
ALTEX|April 10, 2021
Applying evidence-based methods to the development and use of adverse outcome pathwaysRob B M De Vries, Michelle Angrish, Patience Browne, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Nuclear Medicine and Biology|October 1, 1996
Synthesis and preliminary evaluation of (S)-(2-[18F]fluoro-4,5-dihydroxyphenyl)-2-methyl L-alanine, (S)-[18F]-FMEDOPA, a potentially improved imaging agent for the presynaptic dopaminergic nervous systemY Yost, T Conway
Journal of Pharmaceutical Sciences|September 1, 1979
Resolution of (+/-)-propranololY Yost, J L Holtzman
Carcinogenesis|January 1, 1982
Effects of prolonged oral treatment with N-fluoren-4-ylacetohydroxamic acid on rat liver fine structureB Flaks, Y Yost, A Flaks
Cancer Research|February 1, 1975
The carcinogenicity of fluorenylhydroxamic acids and N-acetoxy-N-fluorenylacetamides for the rat as related to the reactivity of the esters toward nucleophilesY Yost, H R Gutmann, R E Rydell
Cancer Research|June 1, 1971
Activation of the carcinogen, N-hydroxy-2-fluorenylbenzene-sulfonamide, by desulfonylation to N-2-fluorenylhydroxylamine in vivoD Malejka-Giganti, H R Gutmann, R E Rydell, et al.
Molecular Pharmacology|November 1, 1981
Application of spin labeling to drug assays. II. Determination of the binding of [14C]-phenytoin and spin-labeled phenytoins to albumin and human serumD Chou, C F Polnaszek, Y Yost, et al.
Biochemical Pharmacology|May 25, 1993
Nitroxyl analogs as inhibitors of aldehyde dehydrogenase. C-nitroso compoundsH T Nagasawa, Y Yost, J A Elberling, et al.
Cancer Research|May 1, 1970
Structure-activity relationships of N-acylarylhydroxylamines in the ratH R Gutmann, D S Leaf, Y Yost, et al.
ALTEX|April 10, 2021
Applying evidence-based methods to the development and use of adverse outcome pathwaysRob B M De Vries, Michelle Angrish, Patience Browne, et al.
Pageof 1